drugset / Trial / NCT04156750

A Study of LY3556050 in Healthy Participants

NCT04156750

Phase 1 Completed 34 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.

Timeline

Start
2019-11-20
Primary completion
2020-08-03
Completion
2020-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Iohexol Diagnostic / imaging agent Intravenous
Subject LY3556050 Unknown Oral
Subject Metformin Small molecule Oral

Indications

No indication recorded.